Companies /Healthcare

Lexeo Therapeutics Inc

NASDAQ: LXEO Biotechnology
$3.23
▲ $0.36 (+12.54%) today
Markets closed · 5:41pm ET

LXEO at a Glance

Valuation
Market cap
$235.6M
Profitability
EPS (TTM)
$-1.02
Price
52-week range
$3 – $11
Street target
$20.67
Earnings
Next report
Nov 18, 2026

Headquartered in New York, NY Fiscal year ends December NASDAQ: LXEO lexeotx.com

About Lexeo Therapeutics

Lexeo Therapeutics is a clinical-stage, pre-revenue biotechnology company developing therapies that address the underlying genetic causes of cardiovascular and neurological diseases.

Its two clinical-stage AAV gene therapies use the cardiac-tropic AAVrh.10 capsid:
- LX2006 targets Friedreich ataxia cardiomyopathy. It is in the SUNRISE-FA 2 pivotal study, initiated in June 2026, with topline data expected in 2H 2027 and a potential BLA under accelerated approval in 1H 2028.
- LX2020 targets PKP2 arrhythmogenic cardiomyopathy, which affects about 60,000 people in the U.S. It is in the HEROIC-PKP2 Phase I/II trial and holds RMAT, Orphan Drug and Fast Track designations. A pivotal study is planned for 2H 2027.

Following its September 2026 acquisition of Mantle Therapeutics, Lexeo runs a multimodal Friedreich ataxia platform:
- LX3010, a clinical-stage oral combination.
- LX3030, an oral HDAC inhibitor.
- LX3050, a TfR1-targeted frataxin-replacement fusion protein.
- LX3070, a TfR1-targeted antisense oligonucleotide.

The pipeline also includes preclinical cardiac gene therapies LX2021 (desmoplakin cardiomyopathy) and LX2022 (TNNI3 hypertrophic cardiomyopathy), plus Alzheimer's APOE2-based gene therapy programs (LX1001, LX1021, LX1020). Lexeo has a research collaboration with Johnson & Johnson on cardiac AAV delivery routes. It uses an optimized Sf9 baculovirus manufacturing platform and retains global rights across all programs. Updated

Latest Activity

LXEOLexeo Therapeutics
Q3 2026
EPS
-$0.43
est -$0.32-33.2%
Revenue
$0K

The wider loss is the cost of two pivotal programs moving at once, with R&D more than doubling to $34.5 million on the Mantle acquisition and an LX2006 milestone. What actually moves this $236 million biotech is the gene therapy data released alongside it: an 80% mean reduction in non-sustained ventricular tachycardia in high-dose LX2020 patients, with the FDA open to that endpoint for a pivotal study starting in 2H 2027.

Quarterly EPS — reported vs estimate

LXEO Coverage

Frequently Asked Questions

What does Lexeo Therapeutics do?

Lexeo Therapeutics is a clinical-stage, pre-revenue biotechnology company developing therapies that address the underlying genetic causes of cardiovascular and neurological diseases. Its two clinical-stage AAV gene therapies use the cardiac-tropic AAVrh.10 capsid: - LX2006 targets Friedreich ataxia cardiomyopathy.

What is the LXEO stock price target?

The Wall Street consensus 12-month price target for LXEO is $20.67.